RT Journal Article
SR Electronic
T1 Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4759
OP 4766
DO 10.21873/anticanres.12784
VO 38
IS 8
A1 MOCHIZUKI, KUNIO
A1 KAWAI, MASATAKA
A1 ODATE, TORU
A1 TAHARA, IPPEI
A1 INOUE, TOMOHIRO
A1 KASAI, KAZUNARI
A1 NAKAZAWA, TADAO
A1 KATOH, RYOHEI
A1 KONDO, TETSUO
YR 2018
UL http://ar.iiarjournals.org/content/38/8/4759.abstract
AB Background/Aim: Immunohistochemistry was used to evaluate 600 carcinomas of major histological types from various organs to determine the tissue distributions of the novel markers prostein, uroplakin II and SATB2. Materials and Methods: We retrieved 30 cases from 20 different carcinomas of systemic organs. Results: All prostate adenocarcinomas were immunopositive for prostein, and its reactivity was consistently diffuse. There was faint labeling of prostein in few cases of the 570 non-prostatic carcinomas. Uroplakin II was immunopositive in 53% and 60% of urothelial carcinomas (UC) of the bladder and the ureter, respectively. There was focal and weak positivity of uroplakin II in a few cases of non-urinary tract carcinomas. SATB2 was frequently positive in adenocarcinomas of the digestive organs, and was also expressed in a minority of the non-colorectal adenocarcinomas. Conclusion: Prostein and uroplakin II are immunohistochemical biomarkers of prostate adenocarcinomas and UCs of the urinary tract.